propafenone + sotalol + dronedarone + amiodarone combination

This combination refers to four separate antiarrhythmic medications used individually or in simpler combinations for treating atrial fibrillation. Propafenone is a Class IC agent with beta-blocking activity. Sotalol is a Class III agent with beta-blocking properties, associated with torsades de pointes risk at higher doses. Dronedarone is a Class III agent similar to amiodarone but with fewer side effects, associated with lower proarrhythmia risk than sotalol but less effective than amiodarone for maintaining sinus rhythm. Amiodarone is the most effective Class III agent for maintaining sinus rhythm but has the highest rate of serious adverse events, significant drug interactions, and potential mortality increase in some populations. These four drugs are not typically administered together as a single combination drug product. Clinical studies have compared the individual drugs, showing amiodarone as most effective for sinus rhythm maintenance, and dronedarone associated with lower all-cause death compared to sotalol. Dronedarone also shows a lower rate of proarrhythmic events. While isolated reports exist of two-drug combinations (e.g., amiodarone + propafenone, sotalol + propafenone), the combination of all four is not standard practice. Drug selection typically depends on patient factors, comorbidities, proarrhythmia risk, interactions, and organ function.